美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Franklin Genomic Advancements ETF

42.64

+0.78781.88%

盘后：42.640.00000.00%16:10 EDT

成交量：13.10万

成交额：561.31万

市值：2,984.80万

市盈率：- -

高：42.85

开：42.26

低：42.26

收：41.85

52周最高：45.58

52周最低：31.44

股本：70.00万

流通股本：70.00万

量比：80.11

换手率：18.72%

股息：0.14

股息率：0.34%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

小分子生物技术公司Iambic Therapeutics(IAM.US)IPO定价15-17美元/股拟筹资1.5亿美元

专注于自身免疫性疾病和炎症性疾病的早期生物技术公司TRex Bio Inc.在美国首次公开募股（IPO）中筹资1.167

Guardant Health Inc(GH)股票10月6日盘中下跌8.27%：背后推手曝光

TradingKey中文

Natera Inc(NTRA)股票10月6日盘中下跌5.30%：释放什么信号？

TradingKey中文

Forbion募资26亿美元，为欧洲生物技术行业注入强心剂

环球市场播报

鲁比奥：美国制药和生物技术企业在冰岛面临切实机遇。

Alliance Foundation Trials携手Natera启动AFT-70 Navigate：一项评估基因泰克口服选择性雌激素受体降解剂联合Signatera™ MRD指导的CDK4/6抑制剂治疗乳腺癌的全球随机III期试验

精准基因编辑、蛋白质电子转移、自组装单分子层，谁能摘得诺贝尔化学奖？两位专家给出他们的判断

亦辰集团：拟收购曜辉华医电51%股权布局精准医疗业务

南方财经网

Ligand与Avencell达成融资协议，最高4700万美元助推新一代CAR-T疗法研发管线

Anthropic：Claude主导发现了一种分子机器可能代表一种新的基因编辑机制

Anthropic：Claude 识别新型酶系统，基因编辑股走低

Anthropic IPO前亮科研牌：Claude“自主发现”类CRISPR系统，基因编辑板块遭遇“AI替代焦虑”

从技术并跑到落地困境，中国基因治疗的商业突围之路

人类疯狂改造番茄，就为了让你吃到维生素D

港股生物技术板块震荡走强，康希诺生物涨超10%

梅奥诊所实验室投资亚洲病理学控股公司和Lifestrands Genomics，以推进诊断和精准医疗。

Natera Inc(NTRA)股票9月22日盘中上涨5.67%：释放什么信号？

TradingKey中文

安进股价盘前大涨逾4%，受第三期临床试验结果提振。

Signatera™在日本获批为肌层浸润性膀胱癌伴随诊断工具

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/HELX/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.64,"timestamp":1791576000000,"preClose":41.8522,"halted":0,"volume":131015,"hourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:10 EDT","volume":1,"amount":42.64,"timestamp":1791576604044,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01882338323911281,"floatShares":700000,"shares":700000,"eps":0,"marketStatus":"休市中","change":0.7878,"latestTime":"10-09 16:00:00 EDT","open":42.26,"high":42.85,"low":42.26,"amount":5613094,"amplitude":0.014097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":41.8522,"sharesOutstanding":650000,"nav":42.701,"aum":29890376.7,"dividendRate":0.003382,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:10 EDT","volume":1,"amount":42.64,"timestamp":1791576604044,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":80.11190559774228,"impliedVol":0.203,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":80.11190559774228,"shares":700000,"dividePrice":0.1442,"high":42.85,"amplitude":0.014097,"preClose":41.8522,"low":42.26,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":42.64,"eps":0,"divideRate":0.003382,"volume":131015,"delay":0,"ttmEps":0,"open":42.26,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":43.79,"twentyDayClose":40.9874,"sixtyDayClose":39.2447},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674836788","title":"小分子生物技术公司Iambic Therapeutics(IAM.US)IPO定价15-17美元/股 拟筹资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674836788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674836788?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 14:50","pubTimestamp":1791528639,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，依托自研人工智能平台开发小分子抗癌疗法、处于一期临床阶段的生物技术公司Iambic Therapeutics于周四公布了其IPO条款。按拟发行价区间中值计算，Iambic Therapeutics的完全摊薄市值将达到8.09亿美元。据了解，Iambic Therapeutics是一家临床阶段的生物技术公司，将专有AI模型与自动化高通量化学和生物学相结合，用于设计小分子药物。Iambic Therapeutics成立于2019年，截至2026年6月30日的过去12个月实现营收1800万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UDN","WDNA","IAM","UUP","BK4539","BK4007","LENZ","IPOS","HELX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674240880","title":"专注于自身免疫性疾病和炎症性疾病的早期生物技术公司TRex Bio Inc.在美国首次公开募股（IPO）中筹资1.167","url":"https://stock-news.laohu8.com/highlight/detail?id=2674240880","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674240880?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 12:13","pubTimestamp":1791519187,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["KCE","TRXB","HELX","IPO","BK4127","LQPE","SPCK","QQQS","REDS","BCSM","IPOS","ACSG","PEVC","FRHC","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068734","title":"Guardant Health Inc(GH)股票10月6日盘中下跌8.27%：背后推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068734","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068734?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 03:16","pubTimestamp":1791314179,"startTime":"0","endTime":"0","summary":"• 经过连续数月的反弹后，获利回吐导致 Guardant Health 股价下跌。\n• 持续亏损和高估值倍数引发了沉重的抛盘压力。\n• 该公司报告的年营收为 9.8202 亿美元，净利润为 -4.1628 亿美元。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262202425-market-movers-gh-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","GNMX","PTH","GNOM","GH","EKG","GDOC","LU0320765992.SGD","BK4196","HELX","FFOX","LFSC","LU0109394709.USD","BK4535","LU0889565916.HKD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673113050","title":"Natera Inc(NTRA)股票10月6日盘中下跌5.30%：释放什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2673113050","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673113050?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 01:16","pubTimestamp":1791306977,"startTime":"0","endTime":"0","summary":"• 受到广泛获利回吐影响，Natera 股价在近期触及高位后出现回调。\n• 偏高的估值以及内部人士减持加剧了近期短期的抛售压力。\n• 核心基本面依然强劲，精准医疗业务组合实现强劲的业务量增长。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262202280-market-movers-ntra-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0012050646.USD","LU2324357040.USD","LU0106261612.USD","LU2065731478.USD","LU2264538146.SGD","LU2065171311.SGD","HELX","BK4139","LU0963586101.USD","GNOM","LU0053671581.USD","LU0345770993.USD","LU0345770308.USD","LU1064131342.USD","LU2065170008.USD","LU2065169927.USD","LU1988902786.USD","LU2065171402.SGD","NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055039","title":"Forbion募资26亿美元，为欧洲生物技术行业注入强心剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055039","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055039?lang=zh_cn&edition=fundamental","pubTime":"2026-10-06 19:54","pubTimestamp":1791287646,"startTime":"0","endTime":"0","summary":"荷兰这家机构完成大额募资；尽管欧洲药企与投资者不断警示，本地区竞争力正在下滑欧洲制药行业高管一直担忧生物技术领域资金供给不足。总部位于荷兰的 Forbion 是欧洲头部生物技术投资机构，本次募资规模达 23 亿欧元，是 2026 年欧洲募资额最高的生命科学风险投资基金。Forbion 表示，本次资金约 60% 来自欧洲本土投资者，40% 来自北美。Forbion 主要投资欧洲与北美的生命科学企业，覆盖多个治疗赛道。本次大额募资出炉之际，欧洲制药行业高层正敲响行业警钟。","market":"us","thumbnail":"http://n.sinaimg.cn/finance/transform/116/w550h366/20261006/e000-dcc4cfe0fc12e5d7ca640d410a0d8283.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/finance/transform/116/w550h366/20261006/e000-dcc4cfe0fc12e5d7ca640d410a0d8283.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-06/doc-iniuhyrf5491331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673605367","title":"鲁比奥：美国制药和生物技术企业在冰岛面临切实机遇。","url":"https://stock-news.laohu8.com/highlight/detail?id=2673605367","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673605367?lang=zh_cn&edition=fundamental","pubTime":"2026-10-06 18:51","pubTimestamp":1791283902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WDNA","RSPH","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186296044","title":"Alliance Foundation Trials携手Natera启动AFT-70 Navigate：一项评估基因泰克口服选择性雌激素受体降解剂联合Signatera™ MRD指导的CDK4/6抑制剂治疗乳腺癌的全球随机III期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1186296044","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186296044?lang=zh_cn&edition=fundamental","pubTime":"2026-10-05 20:08","pubTimestamp":1791202099,"startTime":"0","endTime":"0","summary":"Alliance Foundation Trials与Natera共同宣布启动AFT-70 Navigate研究——这是一项全球性、随机对照的III期临床试验，旨在评估基因泰克（Genentech）研发的口服选择性雌激素受体降解剂（SERD），结合Signatera™分子残留病灶（MRD）指导下的CDK4/6抑制剂疗法，用于乳腺癌患者的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU2065169927.USD","LU0012050646.USD","HELX","LU0106261612.USD","LU0053671581.USD","NTRA","LU1064131342.USD","LU2065171402.SGD","BK4139","LU2264538146.SGD","LU0963586101.USD","LU0345770993.USD","LU2065170008.USD","LU2065731478.USD","LU2324357040.USD","LU1988902786.USD","GNOM","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672072209","title":"精准基因编辑、蛋白质电子转移、自组装单分子层，谁能摘得诺贝尔化学奖？两位专家给出他们的判断","url":"https://stock-news.laohu8.com/highlight/detail?id=2672072209","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672072209?lang=zh_cn&edition=fundamental","pubTime":"2026-10-04 07:37","pubTimestamp":1791070620,"startTime":"0","endTime":"0","summary":"2026年诺贝尔化学奖将于北京时间10月7日傍晚揭晓。根据该公司9月公布的最新名单，化学领域涉及三组研究成果，分别是精准基因编辑、自组装单分子层、蛋白质长程电子转移。宋延林更看好精准基因编辑的潜在影响，姜雪峰则更倾向于蛋白质长程电子转移的基础科学价值。今年，阿拉拉、努佐和萨吉夫因发展自组装单分子层入选“引文桂冠”。对于自组装单分子层是否有望获得此次2026年诺贝尔化学奖，姜雪峰和宋延林的判断较为保留。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-10-04/doc-initzerr5746875.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-10-04/doc-initzerr5746875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XT","KOMP","NBDS","SYNB","TARK","DTEC","WDNA","BMED","FWD","IDNA","GNOM","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670233040","title":"亦辰集团：拟收购曜辉华医电51%股权 布局精准医疗业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2670233040","media":"南方财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670233040?lang=zh_cn&edition=fundamental","pubTime":"2026-09-28 17:38","pubTimestamp":1790588280,"startTime":"0","endTime":"0","summary":"南财智讯9月28日电，亦辰集团（08365.HK）发布自愿公告，2026年9月28日，公司与卖方订立买卖协议，拟收购曜辉华医电（香港）有限公司51%已发行股本。目标公司主要从事癌症筛查暨早期检测中心营运、人工智能数字病理及提供癌症诊疗整厂输出解决方案。收购事项完成后，公司将协助目标公司进行集资活动，并提供或安排提供会计、公司秘书及企业融资等服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885280242.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885280242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TYNE","XT","DTEC","BK1147","HELX","BMED","08365","GNMX","KOMP","SYNB","GNOM","HTEC","WDNA","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199226181","title":"Ligand与Avencell达成融资协议，最高4700万美元助推新一代CAR-T疗法研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1199226181","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199226181?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 19:01","pubTimestamp":1790247668,"startTime":"0","endTime":"0","summary":"Ligand与Avencell Therapeutics签署融资协议，以最高4700万美元的资金支持新一代CAR-T细胞治疗产品管线的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","LU0566484027.USD","BK4007","LGND","IE0009354923.USD","BK4139","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669045569","title":"Anthropic：Claude主导发现了一种分子机器 可能代表一种新的基因编辑机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2669045569","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669045569?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 11:08","pubTimestamp":1790219336,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IDNA","FWD","NBDS","DTEC","WDNA","TARK","XT","SYNB","KOMP","GNOM","HELX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669587244","title":"Anthropic：Claude 识别新型酶系统，基因编辑股走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2669587244","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669587244?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 09:37","pubTimestamp":1790213830,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，当地时间周三，Anthropic 宣布其模型 Claude 在海量 DNA 序列数据中识别出一种此前未被完整描述的酶系统，重复序列排列方式与 CRISPR 相似。这是其新设生物实验室的首项成果，团队于今年春季组建，实验室位于旧金山湾区。消息公布后，基因编辑公司股价周三走低，CRISPR Therapeutics 跌 5.54%，Beam Therapeutics 跌 6.02%，Prime Medicine 跌 11.58%。相关任务是从大型 DNA 数据库中寻找值得研究的逆转录酶系统。约 21 小时搜索中，约 950 个 Claude 智能体共使用约 2.1 亿个 token，其中一个智能体注意到某种逆转录酶基因旁有排列规律的重复 DNA 序列。团队将该组合命名为阵列相关逆转录酶系统，主要存在于噬菌体中，包含逆转录酶基因、相邻伴随基因及一组重复 DNA 序列。逆转录酶本身此前已有研究，新发现是它与周围非编码 DNA 序列及功能未知的伴随蛋白共同构成的系统。Anthropic 表示，研究人员仍不知道该系统的主要功能，也未证明它能像成熟基因编辑工具一样对 DNA 进行定向修改。初步实验发现这些重复序列能产生多种短 RNA，但这不等于已具备可编程基因编辑能力。预印本论文披露，为检验能否重复发现，团队又运行 10 次相同搜索； ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2291919","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FWD","KOMP","BMED","WDNA","XT","GNOM","SYNB","HELX","NBDS","TARK","DTEC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669843417","title":"Anthropic IPO前亮科研牌：Claude“自主发现”类CRISPR系统，基因编辑板块遭遇“AI替代焦虑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669843417","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669843417?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 07:21","pubTimestamp":1790205689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARTY","HELX","REDS","ARKG","VTHR","QTOC","SYNB","LU1861558580.USD","FWD","BMED","AIPO","IDNA","KCE","XT","GNOM","KOMP","LU1861559042.SGD","CRSP","TARK","BK4139","BK4611","DTEC","BK4585","BK4127","BK4556","NBDS","WDNA","FRHC","BK4588","AGIX","IPOS","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485869","title":"从技术并跑到落地困境，中国基因治疗的商业突围之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485869","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669485869?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 20:06","pubTimestamp":1790165189,"startTime":"0","endTime":"0","summary":"当前，基因治疗正站在一个尴尬的节点上：技术能力在加速，而支付与监管能力正在成为一个新的瓶颈。2026年，基因治疗的全球图景呈现明显的“两极分化”。在美国和欧洲，基因治疗的适应症持续扩展：美国食品药品监督管理局（FDA）将基因疗法Casgevy的适用年龄下调至2岁；欧盟批准了Itvisma覆盖更广泛的脊髓性肌萎缩症（SMA）人群。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882617632.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882617632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FWD","BMED","IDNA","KOMP","WDNA","XT","SYNB","DTEC","NBDS","SMA","BK4217","TARK","GNOM","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669487698","title":"人类疯狂改造番茄，就为了让你吃到维生素D","url":"https://stock-news.laohu8.com/highlight/detail?id=2669487698","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669487698?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 18:53","pubTimestamp":1790160780,"startTime":"0","endTime":"0","summary":"最近几年，越来越多的科学家疯狂改造番茄，试图让它为人类生产维生素D。对人类来说，这属于暴殄天物，必须整改。在这篇研究中，约翰·英纳斯中心的科学家们还宣称，由于生化通路类似，除了番茄，同为茄科的马铃薯、辣椒也是生产维生素D3原料的潜力选手。吃这种番茄，已经快赶上直接吃复合维生素片了。所以，想要直接吃新鲜番茄补D3的人可能要失望了；这是最不能让人接受的，就是新鲜番茄仍然不含维生素D3。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656207372&idx=3&sn=9706ce4606cfb02c82f1bab42fcf5ce6&chksm=677a3bb1d7b56cc09004ce87616d255d453911132b60fea923f3f7559a599b693034b8901db2&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["NVDS","NVDB","LU2083900584.USD","07788","IDNA","DTEC","BMED","IPOS","TARK","LU0267386448.USD","LU1861127337.USD","NVC","NVDU","LU1066051225.USD","FWD","NVDX","NVDL","NVDQ","NVYY","NVII","XT","LU1496350171.SGD","LU1066051498.USD","HELX","LU1066051811.HKD","NVDO","KOMP","NVDW","LU1633808545.USD","07388","NBDS","NVDY","LU0077335932.USD","LU0786609619.USD","SYNB","ANV","WDNA","LU0170899867.USD","NVDG","NVDD","GNOM","LU1066053197.SGD","DIPS","LU0234572021.USD","LU1804176565.USD","LU1914381329.SGD","NVD","LU2265009873.SGD","LU0127658192.USD","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669217488","title":"港股生物技术板块震荡走强，康希诺生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669217488","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669217488?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 11:14","pubTimestamp":1790133289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KCAI","VXUS","WDNA","BK4588","HELX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669176439","title":"梅奥诊所实验室投资亚洲病理学控股公司和Lifestrands Genomics，以推进诊断和精准医疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669176439","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669176439?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 09:30","pubTimestamp":1790127028,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HTEC","XT","DTEC","WDNA","SYNB","IDNA","GDOC","HELX","GNMX","KOMP","TYNE","BMED","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669218131","title":"Natera Inc(NTRA)股票9月22日盘中上涨5.67%：释放什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2669218131","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669218131?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 02:16","pubTimestamp":1790100984,"startTime":"0","endTime":"0","summary":"• Natera 的临床里程碑和 Signatera 的临床验证进一步提振了投资者信心。\n• 管理层强调检测应用正在加速普及，且长期毛利率有望持续扩大。\n• 华尔街情绪保持积极，多位分析师给予“买入”评级。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262181076-market-movers-ntra-20260922","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2264538146.SGD","BK4139","LU0963586101.USD","LU1064131342.USD","LU2065169927.USD","LU1988902786.USD","GNOM","NTRA","LU2065171311.SGD","LU0053671581.USD","LU2065731478.USD","HELX","LU0345770308.USD","LU2065171402.SGD","LU0106261612.USD","LU2065170008.USD","LU0345770993.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114208","title":"安进股价盘前大涨逾4%，受第三期临床试验结果提振。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669114208?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 21:07","pubTimestamp":1790082475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","RSPH","TBXU","IEHS","PSCH","WDNA","PBE","XPH","IEIH","LU0320765992.SGD","IDNA","BK4599","LU2272731865.HKD","BBH","SBIO","FTXH","BBP","FBT","PPH","SYNB","LU0109394709.USD","LU2242646821.SGD","AMGN","MRNX","LU0058720904.USD","IYH","IBB","BK4585","PBPH","LFSC","BIB","LU2473716301.USD","PJP","IE00B5TLWC47.USD","RXL","MEDI","CANC","TMED","IE00B4R5TH58.HKD","LU0122379950.USD","LU1992135472.HKD","HELX","LU2272731782.SGD","BME","AZNH","BIOY","GNOM","MRNY","IBRN","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136180716","title":"Signatera™在日本获批为肌层浸润性膀胱癌伴随诊断工具","url":"https://stock-news.laohu8.com/highlight/detail?id=1136180716","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136180716?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 20:01","pubTimestamp":1790078476,"startTime":"0","endTime":"0","summary":"Signatera™在日本获得监管批准，正式成为肌层浸润性膀胱癌领域的伴随诊断产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4139","LU0106261612.USD","LU2324357040.USD","LU2065169927.USD","LU2065171402.SGD","LU0012050646.USD","LU0963586101.USD","LU1988902786.USD","LU2065731478.USD","LU1064131342.USD","LU0345770993.USD","GNOM","LU2264538146.SGD","LU2065170008.USD","HELX","LU0053671581.USD","LU0345770308.USD","NTRA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}